Page last updated: 2024-12-06

relcovaptan

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Relcovaptan is a novel, selective, and orally bioavailable vasopressin V1A receptor antagonist. It is being investigated for the treatment of hyponatremia, a condition characterized by abnormally low sodium levels in the blood. Hyponatremia can be caused by various factors, including heart failure, liver disease, and kidney disease. Relcovaptan has shown promise in clinical trials by promoting water excretion and restoring normal sodium levels. The compound is synthesized using a series of chemical reactions starting from commercially available starting materials. Relcovaptan's importance lies in its potential to provide a safe and effective treatment option for hyponatremia, a condition that can lead to serious complications if left untreated. The study of relcovaptan is driven by the need for new therapies for hyponatremia, particularly for patients with limited treatment options or who experience adverse effects from existing therapies.'

relcovaptan: a nonpeptide vasopressin V1 receptor antagonist; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID60943
CHEMBL ID419667
CHEBI ID93701
SCHEMBL ID4387208
MeSH IDM0218930

Synonyms (51)

Synonym
(2s)-1-(((2r,3s)-5-chloro-3-(o-chlorophenyl)-1-((3,4-dimethoxyphenyl)sulfonyl)-3-hydroxy-2-indolinyl)carbonyl)-2-pyrrolidinecarboxamide
1-(5-chloro-3-(2-chlorophenyl)-1-(3,4-dimethoxybenzenesulfonyl)-3-hydroxy-2,3-dihydro-1h-indole-2-carbonyl)pyrrolidine-2-carboxamide
sr 49059
sr-49059
relcovaptan [inn]
relcovaptan
2-pyrrolidinecarboxamide, 1-((5-chloro-3-(2-chlorophenyl)-1-((3,4-dimethoxyphenyl)sulfonyl)-2,3-dihydro-3-hydroxy-1h-indol-2-yl)carbonyl)-, (2r-(2alpha(s*),3beta))-
tdi-0134
CHEMBL419667 ,
tdi 0134
HMS3268L06
BRD-K96720755-001-01-8
gtpl2200
(2s)-1-[(2r,3s)-5-chloro-3-(2-chlorophenyl)-1-(3,4-dimethoxyphenyl)sulfonyl-3-hydroxy2h-indole-2-carbonyl]pyrrolidine-2-carboxamide
sr49059
NCGC00092366-01
1-[5-chloro-3-(2-chloro-phenyl)-1-(3,4-dimethoxy-benzenesulfonyl)-3-hydroxy-2,3-dihydro-1h-indole-2-carbonyl]-pyrrolidine-2-carboxylic acid amide
bdbm50114031
(s)-1-((2r,3s)-5-chloro-3-(2-chlorophenyl)-1-(3,4-dimethoxyphenylsulfonyl)-3-hydroxyindoline-2-carbonyl)pyrrolidine-2-carboxamide
(2s)-1-[(2r,3s)-5-chloro-3-(2-chlorophenyl)-1-(3,4-dimethoxybenzenesulfonyl)-3-hydroxy-2,3-dihydro-1h-indole-2-carbonyl]-pyrrolidine-2-carboxamide
(2s)-1-[(2r,3s)-5-chloro-3-(2-chlorophenyl)-1-(3,4-dimethoxyphenyl)sulfonyl-3-hydroxy-2h-indole-2-carbonyl]pyrrolidine-2-carboxamide
c1gl8g6g0o ,
150375-75-0
unii-c1gl8g6g0o
(2s)-1-[[(2r,3s)-5-chloro-3-(2-chlorophenyl)-1-[(3,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-hydroxy-1h-indol-2-yl]carbonyl]-2-pyrrolidinecarboxamide
2-pyrrolidinecarboxamide, 1-(((2r,3s)-5-chloro-3-(2-chlorophenyl)-1-((3,4-dimethoxyphenyl)sulfonyl)-2,3-dihydro-3-hydroxy-1h-indol-2-yl)carbonyl)-, (2s)-
[3h] sr 49059
[3h]sr49059
gtpl3482
[3h]sr-49059
[3h]relcovaptan
SCHEMBL4387208
(s)-1-[(2r,3s)-5-chloro-3-(2-chloro-phenyl)-1-(3,4-dimethoxy-benzenesulfonyl)-3-hydroxy-2,3-dihydro-1h-indole-2-carbonyl]-pyrrolidine-2-carboxylic acid amide
AKOS024457044
mfcd00922133
sr-01000945058
SR-01000945058-1
CHEBI:93701
sr 49059, >=97% (hplc)
J-008692
HMS3677E08
DB13929
HMS3413E08
Q7310905
(s)-1-((2r,3s)-5-chloro-3-(2-chlorophenyl)-1-((3,4-dimethoxyphenyl)sulfonyl)-3-hydroxyindoline-2-carbonyl)pyrrolidine-2-carboxamide
P10155
2-pyrrolidinecarboxamide, 1-[[(2r,3s)-5-chloro-3-(2-chlorophenyl)-1-[(3,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-hydroxy-1h-indol-2-yl]carbonyl]-, (2s)-
MS-30780
2-pyrrolidinecarboxamide,1-[[(2r,3s)-5-chloro-3-(2-chlorophenyl)-1-[(3,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-hydroxy-1h-indol-2-yl]carbonyl]-,(2s)-
CS-0007471
HY-18345

Research Excerpts

Overview

Relcovaptan (SR 49059) is a non-peptide, orally active vasopressin V1a receptor inhibitor.

ExcerptReferenceRelevance
"Relcovaptan (SR 49059) is a non-peptide, orally active vasopressin V1a receptor inhibitor. "( The effect of relcovaptan (SR 49059), an orally active vasopressin V1a receptor antagonist, on uterine contractions in preterm labor.
Akerlund, M; Bossmar, T; Brouard, R; Laudanski, T; Le-Fur, G; Olofsson, P; Steinwall, M; Urban, R; Wolff, K, 2005
)
2.13

Pharmacokinetics

ExcerptReferenceRelevance
" The aim of this study was to assess its tolerability and to determine both its pharmacokinetic and pharmacodynamic profiles."( Safety, tolerability, and pharmacokinetics of SR 49059, a V1a vasopressin receptor antagonist, after repeated oral administration in healthy volunteers.
Brouard, R; Donat, F; Dreux, F; Fournie, D; Jang, H; Laporte, V; Lockwood, G; Pignol, R; Serradeil Le Gal, C, 1998
)
0.3

Dosage Studied

ExcerptRelevanceReference
") pretreatment with the alpha 1-adrenoceptor antagonist, prazosin, caused the dose-response curve for the effect of gamma 2-MSH on MAP to shift to the right with a decrease in slope, whereas it had no effect on the dose-response curve for the effect on HR."( Influence of blockade of alpha 1-adrenoceptors, beta 1-adrenoceptors and vasopressin V1A receptors on the cardiovascular effects of gamma 2-melanocyte-stimulating hormone (gamma 2-MSH).
De Wildt, DJ; De Winter, TY; Van Bergen, P; Versteeg, DH, 1997
)
0.3
" In turn, AVT had a dual effect on killifish opercular Isc: an immediate response (~3min) with Isc reduction in an inverted bell-shaped dose-response manner with higher current decrease (-22 μA⋅cm(-2)) at 10(-8) M AVT, and a sustained dose-dependent stimulation of Cl(-) secretion (stable up to 1h), with a threshold significant effect at 10(-8) M and maximal stimulation (~20 μA⋅cm(-2)) at 10(-6)M."( AVT and IT regulate ion transport across the opercular epithelium of killifish (Fundulus heteroclitus) and gilthead sea bream (Sparus aurata).
Fuentes, J; Mancera, JM; MartínezRodríguez, G; Martos-Sitcha, JA, 2015
)
0.42
" Under this condition, we constructed dose-response curves analyzing the effect of local spinal oxytocin (0."( Oxytocin inhibits the rat medullary dorsal horn Sp5c/C1 nociceptive transmission through OT but not V
Condés-Lara, M; García-Boll, E; González-Hernández, A; Martínez-Lorenzana, G, 2018
)
0.48
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
proline derivativeAn amino acid derivative resulting from reaction of proline at the amino group or the carboxy group, or from the replacement of any hydrogen of proline by a heteroatom. The definition normally excludes peptides containing proline residues.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (29)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, CruzipainTrypanosoma cruziPotency39.81070.002014.677939.8107AID1476
15-lipoxygenase, partialHomo sapiens (human)Potency15.84890.012610.691788.5700AID887
phosphopantetheinyl transferaseBacillus subtilisPotency19.95260.141337.9142100.0000AID1490
thyroid stimulating hormone receptorHomo sapiens (human)Potency19.95260.001318.074339.8107AID926
mitogen-activated protein kinase 1Homo sapiens (human)Potency3.98110.039816.784239.8107AID995
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency35.48130.00798.23321,122.0200AID2546
peripheral myelin protein 22Rattus norvegicus (Norway rat)Potency36.12540.005612.367736.1254AID624032
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency1.99530.031610.279239.8107AID884; AID885
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency1.99531.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency1.99531.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency1.99531.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency1.99531.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency1.99531.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency1.99531.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency1.99531.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency1.99531.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency1.99531.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency1.99531.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency1.99531.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency1.99531.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency1.99531.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency1.99531.000012.224831.6228AID885
GABA theta subunitRattus norvegicus (Norway rat)Potency1.99531.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency1.99531.000012.224831.6228AID885
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Vasopressin V2 receptorHomo sapiens (human)Ki0.17800.00040.43453.9811AID217391
Vasopressin V1a receptorRattus norvegicus (Norway rat)Ki0.00140.00080.03000.1100AID217234
Vasopressin V2 receptorSus scrofa (pig)Ki0.28500.28500.28500.2850AID217688
Vasopressin V1a receptorHomo sapiens (human)IC50 (µMol)0.01300.00060.38352.0000AID622731
Vasopressin V1a receptorHomo sapiens (human)Ki0.00090.00020.62357.0300AID1409546; AID1409547; AID217085; AID298221; AID298222; AID298223; AID298224; AID298225; AID337610
Vasopressin V2 receptor Rattus norvegicus (Norway rat)Ki0.28500.00030.97919.7000AID217688
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (36)

Processvia Protein(s)Taxonomy
positive regulation of systemic arterial blood pressureVasopressin V2 receptorHomo sapiens (human)
renal water retentionVasopressin V2 receptorHomo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayVasopressin V2 receptorHomo sapiens (human)
activation of adenylate cyclase activityVasopressin V2 receptorHomo sapiens (human)
hemostasisVasopressin V2 receptorHomo sapiens (human)
positive regulation of cell population proliferationVasopressin V2 receptorHomo sapiens (human)
negative regulation of cell population proliferationVasopressin V2 receptorHomo sapiens (human)
positive regulation of gene expressionVasopressin V2 receptorHomo sapiens (human)
telencephalon developmentVasopressin V2 receptorHomo sapiens (human)
response to cytokineVasopressin V2 receptorHomo sapiens (human)
positive regulation of intracellular signal transductionVasopressin V2 receptorHomo sapiens (human)
cellular response to hormone stimulusVasopressin V2 receptorHomo sapiens (human)
positive regulation of vasoconstrictionVasopressin V2 receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayVasopressin V2 receptorHomo sapiens (human)
regulation of systemic arterial blood pressure by vasopressinVasopressin V2 receptorHomo sapiens (human)
maternal aggressive behaviorVasopressin V1a receptorHomo sapiens (human)
positive regulation of systemic arterial blood pressureVasopressin V1a receptorHomo sapiens (human)
generation of precursor metabolites and energyVasopressin V1a receptorHomo sapiens (human)
activation of phospholipase C activityVasopressin V1a receptorHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationVasopressin V1a receptorHomo sapiens (human)
negative regulation of female receptivityVasopressin V1a receptorHomo sapiens (human)
grooming behaviorVasopressin V1a receptorHomo sapiens (human)
blood circulationVasopressin V1a receptorHomo sapiens (human)
positive regulation of cell population proliferationVasopressin V1a receptorHomo sapiens (human)
positive regulation of heart rateVasopressin V1a receptorHomo sapiens (human)
positive regulation of glutamate secretionVasopressin V1a receptorHomo sapiens (human)
myotube differentiationVasopressin V1a receptorHomo sapiens (human)
calcium-mediated signalingVasopressin V1a receptorHomo sapiens (human)
telencephalon developmentVasopressin V1a receptorHomo sapiens (human)
positive regulation of cell growthVasopressin V1a receptorHomo sapiens (human)
positive regulation of prostaglandin biosynthetic processVasopressin V1a receptorHomo sapiens (human)
positive regulation of cellular pH reductionVasopressin V1a receptorHomo sapiens (human)
social behaviorVasopressin V1a receptorHomo sapiens (human)
cellular response to water deprivationVasopressin V1a receptorHomo sapiens (human)
maternal behaviorVasopressin V1a receptorHomo sapiens (human)
sperm ejaculationVasopressin V1a receptorHomo sapiens (human)
response to corticosteroneVasopressin V1a receptorHomo sapiens (human)
negative regulation of transmission of nerve impulseVasopressin V1a receptorHomo sapiens (human)
transport across blood-brain barrierVasopressin V1a receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayVasopressin V1a receptorHomo sapiens (human)
positive regulation of vasoconstrictionVasopressin V1a receptorHomo sapiens (human)
cellular response to hormone stimulusVasopressin V1a receptorHomo sapiens (human)
regulation of systemic arterial blood pressure by vasopressinVasopressin V1a receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (6)

Processvia Protein(s)Taxonomy
vasopressin receptor activityVasopressin V2 receptorHomo sapiens (human)
protein bindingVasopressin V2 receptorHomo sapiens (human)
peptide bindingVasopressin V2 receptorHomo sapiens (human)
vasopressin receptor activityVasopressin V1a receptorHomo sapiens (human)
protein kinase C bindingVasopressin V1a receptorHomo sapiens (human)
protein bindingVasopressin V1a receptorHomo sapiens (human)
peptide hormone bindingVasopressin V1a receptorHomo sapiens (human)
V1A vasopressin receptor bindingVasopressin V1a receptorHomo sapiens (human)
peptide bindingVasopressin V1a receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (8)

Processvia Protein(s)Taxonomy
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
endosomeVasopressin V2 receptorHomo sapiens (human)
endoplasmic reticulumVasopressin V2 receptorHomo sapiens (human)
Golgi apparatusVasopressin V2 receptorHomo sapiens (human)
plasma membraneVasopressin V2 receptorHomo sapiens (human)
membraneVasopressin V2 receptorHomo sapiens (human)
endocytic vesicleVasopressin V2 receptorHomo sapiens (human)
clathrin-coated endocytic vesicle membraneVasopressin V2 receptorHomo sapiens (human)
perinuclear region of cytoplasmVasopressin V2 receptorHomo sapiens (human)
plasma membraneVasopressin V2 receptorHomo sapiens (human)
endosomeVasopressin V1a receptorHomo sapiens (human)
plasma membraneVasopressin V1a receptorHomo sapiens (human)
endocytic vesicleVasopressin V1a receptorHomo sapiens (human)
plasma membraneVasopressin V1a receptorHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (39)

Assay IDTitleYearJournalArticle
AID708964Increase in urine osmolarity in nephrogenic diabetes insipidus patient harboring V2R del62-64, W164S, R137H mutant after 3 days2012Journal of medicinal chemistry, Dec-27, Volume: 55, Issue:24
Small molecules that target protein misfolding.
AID298221Inhibition of human vasopressin V1a receptor expressed in CHO cells by polarisation binding assay using 96-well plate membranes2007Journal of medicinal chemistry, Oct-04, Volume: 50, Issue:20
Toward efficient drug screening by homogeneous assays based on the development of new fluorescent vasopressin and oxytocin receptor ligands.
AID298224Inhibition of human vasopressin V1a receptor expressed in COS7 cells by HTRF-FRET assay using 96-well plate membranes2007Journal of medicinal chemistry, Oct-04, Volume: 50, Issue:20
Toward efficient drug screening by homogeneous assays based on the development of new fluorescent vasopressin and oxytocin receptor ligands.
AID217688Binding affinity at Vasopressin V2 receptor, performed using [3H]AVP on rat kidney2002Journal of medicinal chemistry, Jun-06, Volume: 45, Issue:12
Synthesis and pharmacological evaluation of 5-(4-biphenyl)-3-methyl-4-phenyl-1,2,4-triazole derivatives as a novel class of selective antagonists for the human vasopressin V(1A) receptor.
AID298225Inhibition of human vasopressin V1a receptor expressed in COS7 cells by HTRF-FRET assay using 384-well plate membranes2007Journal of medicinal chemistry, Oct-04, Volume: 50, Issue:20
Toward efficient drug screening by homogeneous assays based on the development of new fluorescent vasopressin and oxytocin receptor ligands.
AID708965Reduction in urine output in nephrogenic diabetes insipidus patient harboring V2R del62-64, W164S, R137H mutant after 3 days2012Journal of medicinal chemistry, Dec-27, Volume: 55, Issue:24
Small molecules that target protein misfolding.
AID217085Binding affinity at cloned human Vasopressin V1a receptor stably expressed in CHO cells, using [3H]AVP as radioligand2002Journal of medicinal chemistry, Jun-06, Volume: 45, Issue:12
Synthesis and pharmacological evaluation of 5-(4-biphenyl)-3-methyl-4-phenyl-1,2,4-triazole derivatives as a novel class of selective antagonists for the human vasopressin V(1A) receptor.
AID217234Binding affinity at Vasopressin V1a receptor, performed using [3H]AVP on rat liver2002Journal of medicinal chemistry, Jun-06, Volume: 45, Issue:12
Synthesis and pharmacological evaluation of 5-(4-biphenyl)-3-methyl-4-phenyl-1,2,4-triazole derivatives as a novel class of selective antagonists for the human vasopressin V(1A) receptor.
AID217532Selectivity ratio of affinity at human Vasopressin V2 receptor to that of human Vasopressin V1a receptor.2002Journal of medicinal chemistry, Jun-06, Volume: 45, Issue:12
Synthesis and pharmacological evaluation of 5-(4-biphenyl)-3-methyl-4-phenyl-1,2,4-triazole derivatives as a novel class of selective antagonists for the human vasopressin V(1A) receptor.
AID1409546Displacement of [125I]OH-Phpa-LVA from human V1A receptor expressed in CHO cells after 4 hrs by gamma counter analysis2018Journal of medicinal chemistry, 11-21, Volume: 61, Issue:22
Receptor-Ligand Interaction Measured by Inductively Coupled Plasma Mass Spectrometry and Selenium Labeling.
AID622731Antagonist activity at human V1A receptor expressed in CHO cells assessed as inhibition of AVP-induced intracellular calcium release after 30 seconds by FLIPR assay2011Bioorganic & medicinal chemistry letters, Oct-01, Volume: 21, Issue:19
Discovery of PF-184563, a potent and selective V1a antagonist for the treatment of dysmenorrhoea. The influence of compound flexibility on microsomal stability.
AID298223Inhibition of human vasopressin V1a receptor expressed in COS7 cells by HTRF-FRET assay using 96-well plate cells2007Journal of medicinal chemistry, Oct-04, Volume: 50, Issue:20
Toward efficient drug screening by homogeneous assays based on the development of new fluorescent vasopressin and oxytocin receptor ligands.
AID337610Binding affinity to vasopressin V1a receptor1994Journal of natural products, Oct, Volume: 57, Issue:10
Khusimol, a non-peptide ligand for vasopressin V1a receptors.
AID298222Inhibition of human vasopressin V1a receptor expressed in CHO cells by polarisation binding assay using 384-well plate membranes2007Journal of medicinal chemistry, Oct-04, Volume: 50, Issue:20
Toward efficient drug screening by homogeneous assays based on the development of new fluorescent vasopressin and oxytocin receptor ligands.
AID217391Binding affinity at cloned human Vasopressin V2 receptor stably expressed in CHO cells, using [3H]AVP as radioligand2002Journal of medicinal chemistry, Jun-06, Volume: 45, Issue:12
Synthesis and pharmacological evaluation of 5-(4-biphenyl)-3-methyl-4-phenyl-1,2,4-triazole derivatives as a novel class of selective antagonists for the human vasopressin V(1A) receptor.
AID1409547Displacement of [Se-Se]-AVP from human V1A receptor expressed in CHO cells after 4 hrs by RP-LC-ICPMS analysis2018Journal of medicinal chemistry, 11-21, Volume: 61, Issue:22
Receptor-Ligand Interaction Measured by Inductively Coupled Plasma Mass Spectrometry and Selenium Labeling.
AID217693Selectivity ratio (Ki) of affinity at rat Vasopressin V2 receptor to that of rat Vasopressin V1a receptor2002Journal of medicinal chemistry, Jun-06, Volume: 45, Issue:12
Synthesis and pharmacological evaluation of 5-(4-biphenyl)-3-methyl-4-phenyl-1,2,4-triazole derivatives as a novel class of selective antagonists for the human vasopressin V(1A) receptor.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1346453Human V2 receptor (Vasopressin and oxytocin receptors)1997Endocrinology, Oct, Volume: 138, Issue:10
The human V3 pituitary vasopressin receptor: ligand binding profile and density-dependent signaling pathways.
AID1346432Human V1A receptor (Vasopressin and oxytocin receptors)2001British journal of pharmacology, Jul, Volume: 133, Issue:5
Effects of YM471, a nonpeptide AVP V(1A) and V(2) receptor antagonist, on human AVP receptor subtypes expressed in CHO cells and oxytocin receptors in human uterine smooth muscle cells.
AID1346460Human V1B receptor (Vasopressin and oxytocin receptors)2001British journal of pharmacology, Jul, Volume: 133, Issue:5
Effects of YM471, a nonpeptide AVP V(1A) and V(2) receptor antagonist, on human AVP receptor subtypes expressed in CHO cells and oxytocin receptors in human uterine smooth muscle cells.
AID1346432Human V1A receptor (Vasopressin and oxytocin receptors)2005British journal of pharmacology, Nov, Volume: 146, Issue:5
Selectivity of d[Cha4]AVP and SSR149415 at human vasopressin and oxytocin receptors: evidence that SSR149415 is a mixed vasopressin V1b/oxytocin receptor antagonist.
AID1346432Human V1A receptor (Vasopressin and oxytocin receptors)1998British journal of pharmacology, Dec, Volume: 125, Issue:7
Pharmacological characterization of the human vasopressin receptor subtypes stably expressed in Chinese hamster ovary cells.
AID1346432Human V1A receptor (Vasopressin and oxytocin receptors)1997Endocrinology, Oct, Volume: 138, Issue:10
The human V3 pituitary vasopressin receptor: ligand binding profile and density-dependent signaling pathways.
AID1346460Human V1B receptor (Vasopressin and oxytocin receptors)1997Endocrinology, Oct, Volume: 138, Issue:10
The human V3 pituitary vasopressin receptor: ligand binding profile and density-dependent signaling pathways.
AID1346432Human V1A receptor (Vasopressin and oxytocin receptors)2000Kidney international, Oct, Volume: 58, Issue:4
Binding properties of a selective tritiated vasopressin V2 receptor antagonist, [H]-SR 121463.
AID1346432Human V1A receptor (Vasopressin and oxytocin receptors)1999British journal of obstetrics and gynaecology, Oct, Volume: 106, Issue:10
Receptor binding of oxytocin and vasopressin antagonists and inhibitory effects on isolated myometrium from preterm and term pregnant women.
AID1346432Human V1A receptor (Vasopressin and oxytocin receptors)1994The Journal of biological chemistry, Feb-04, Volume: 269, Issue:5
Molecular cloning, sequencing, and functional expression of a cDNA encoding the human V1a vasopressin receptor.
AID1346453Human V2 receptor (Vasopressin and oxytocin receptors)1998British journal of pharmacology, Dec, Volume: 125, Issue:7
Pharmacological characterization of the human vasopressin receptor subtypes stably expressed in Chinese hamster ovary cells.
AID1346460Human V1B receptor (Vasopressin and oxytocin receptors)1998British journal of pharmacology, Dec, Volume: 125, Issue:7
Pharmacological characterization of the human vasopressin receptor subtypes stably expressed in Chinese hamster ovary cells.
AID1346469Human OT receptor (Vasopressin and oxytocin receptors)2005British journal of pharmacology, Nov, Volume: 146, Issue:5
Selectivity of d[Cha4]AVP and SSR149415 at human vasopressin and oxytocin receptors: evidence that SSR149415 is a mixed vasopressin V1b/oxytocin receptor antagonist.
AID1346453Human V2 receptor (Vasopressin and oxytocin receptors)2001British journal of pharmacology, Jul, Volume: 133, Issue:5
Effects of YM471, a nonpeptide AVP V(1A) and V(2) receptor antagonist, on human AVP receptor subtypes expressed in CHO cells and oxytocin receptors in human uterine smooth muscle cells.
AID1346460Human V1B receptor (Vasopressin and oxytocin receptors)2005British journal of pharmacology, Nov, Volume: 146, Issue:5
Selectivity of d[Cha4]AVP and SSR149415 at human vasopressin and oxytocin receptors: evidence that SSR149415 is a mixed vasopressin V1b/oxytocin receptor antagonist.
AID1346432Human V1A receptor (Vasopressin and oxytocin receptors)2000European journal of biochemistry, Jul, Volume: 267, Issue:13
Conserved aromatic residues in the transmembrane region VI of the V1a vasopressin receptor differentiate agonist vs. antagonist ligand binding.
AID1346469Human OT receptor (Vasopressin and oxytocin receptors)1999British journal of obstetrics and gynaecology, Oct, Volume: 106, Issue:10
Receptor binding of oxytocin and vasopressin antagonists and inhibitory effects on isolated myometrium from preterm and term pregnant women.
AID1346453Human V2 receptor (Vasopressin and oxytocin receptors)2000Kidney international, Oct, Volume: 58, Issue:4
Binding properties of a selective tritiated vasopressin V2 receptor antagonist, [H]-SR 121463.
AID1346432Human V1A receptor (Vasopressin and oxytocin receptors)1997The Journal of biological chemistry, Oct-17, Volume: 272, Issue:42
Mapping peptide-binding domains of the human V1a vasopressin receptor with a photoactivatable linear peptide antagonist.
AID1346453Human V2 receptor (Vasopressin and oxytocin receptors)2000European journal of biochemistry, Jul, Volume: 267, Issue:13
Conserved aromatic residues in the transmembrane region VI of the V1a vasopressin receptor differentiate agonist vs. antagonist ligand binding.
AID1346432Human V1A receptor (Vasopressin and oxytocin receptors)1994Biochemical and biophysical research communications, Feb-28, Volume: 199, Issue:1
Binding of [3H] SR 49059, a potent nonpeptide vasopressin V1a antagonist, to rat and human liver membranes.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (119)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's39 (32.77)18.2507
2000's39 (32.77)29.6817
2010's41 (34.45)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 24.33

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index24.33 (24.57)
Research Supply Index4.87 (2.92)
Research Growth Index4.52 (4.65)
Search Engine Demand Index29.35 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (24.33)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials9 (7.50%)5.53%
Reviews7 (5.83%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other104 (86.67%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]